Literature DB >> 19887076

Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.

Christelle Reperant1, Stéphanie Pons, Eric Dufour, Hans Rollema, Alain M Gardier, Uwe Maskos.   

Abstract

We studied the effects of 1 mg/kg doses of nicotine and the alpha4beta2* nicotinic acetylcholine receptor (nAChR) partial agonist, varenicline, on extracellular dopamine (DA) levels in the nucleus accumbens (NuAcc) of lentivirally vectorized male mice. Three separate experimental groups were injected with a lentiviral vector transducing the ventral tegmental area (VTA): wild-type C57BL/6J mice with a vector expressing eGFP only, beta2 knock-out mice (beta2KO) with the eGFP-only vector, and beta2KO mice with a bicistronic vector reintroducing beta2 and eGFP into the VTA as recently described (Maskos et al., 2005). Our results suggest that the neurochemical effects of varenicline as measured by using microdialysis in awake, freely moving mice are mainly mediated via beta2* nAChR subunits localized in the VTA. 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887076     DOI: 10.1016/j.neuropharm.2009.10.007

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.

Authors:  Nick C Ortiz; Heidi C O'Neill; Michael J Marks; Sharon R Grady
Journal:  Nicotine Tob Res       Date:  2012-01-12       Impact factor: 4.244

Review 2.  Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

Authors:  Dympna Harmey; Patrick R Griffin; Paul J Kenny
Journal:  Nicotine Tob Res       Date:  2012-09-27       Impact factor: 4.244

Review 3.  Recent advances in gene manipulation and nicotinic acetylcholine receptor biology.

Authors:  Anne Tammimäki; William J Horton; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2011-06-16       Impact factor: 5.858

4.  The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Authors:  Kristin M Wildeboer-Andrud; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2011-07-07       Impact factor: 3.533

Review 5.  Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.

Authors:  Luis M Tuesta; Christie D Fowler; Paul J Kenny
Journal:  Biochem Pharmacol       Date:  2011-06-29       Impact factor: 5.858

6.  Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.

Authors:  Tanuja Bordia; Maya Hrachova; Matthew Chin; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2012-05-01       Impact factor: 4.030

Review 7.  Mechanistic insights into nicotine withdrawal.

Authors:  Michael Paolini; Mariella De Biasi
Journal:  Biochem Pharmacol       Date:  2011-07-20       Impact factor: 5.858

8.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

9.  Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons.

Authors:  Dustin W DuBois; Joanne C Damborsky; Annette S Fincher; Gerald D Frye; Ursula H Winzer-Serhan
Journal:  Life Sci       Date:  2013-01-24       Impact factor: 5.037

Review 10.  Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Authors:  Steven J Simmons; Thomas J Gould
Journal:  J Clin Pharm Ther       Date:  2014-05-14       Impact factor: 2.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.